Pfizer expansion in Ireland would lead to 350 jobs

Pfizer HQ

Pfizer’s biologics manufacturing plant in Dublin is one of the largest in the world but will get bigger yet as the drugmaker expands the facility, in part, to up production of one of its biggest-selling drugs. The project will lead to 350 jobs, while allowing Pfizer to expand capacity for Enbrel, even as that drug faces biosimilar competition.

Pfizer ($PFE) earlier confirmed to FiercePharma that it was proposing to expand its Grange Castle site, but offered up no details. An Environmental Impact Study cited by the Irish Times, however, has outlined the New York drugmaker’s plans there. It said Pfizer will invest between €300 million and €400 million ($440.5 million) to build a 5-story, 34,500 square-meter (371,354 square-foot), biologics manufacturing unit. 

The project is planned to be completed in two phases, adding 200 jobs to Pfizer’s Ireland operations with the initial phase and another 100 jobs upon completion of the second. When fully operational, the report said the site will employ 1,450 people.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Pfizer indicated that assuming it gets approval for the expansion, it will start work next year and the expansion is slated to take between 24 and 27 months to complete, so it is shooting for it to be operational in 2020.  

This project follows Pfizer's announcement last month that it would spend $200 million to build a 175,000-square-foot facility at its campus in Andover, MA, also to produce complex biologics and vaccines.

While the Ireland expansion is not solely for production of Enbrel, the drugmaker said the larger facility would allow it to increase capacity of the drug by 50%. Enbrel is among the best sellers in the world, with revenues last year of $5.36 billion for Amgen ($AMGN) and Pfizer which share rights to the product. But its earnings potential is on the wane. They are expected to be down to $4.95 billion in 2020, as biosimilars outside the U.S. where Pfizer holds rights to the drug, gain ground. South Korea's Samsung Bioepis in January won European Commission approval for its copy and has already begun selling it in Norway.

- read the Irish Times story

Related Articles: 
UPDATED: Pfizer planning Ireland biologics plant expansion 
Pfizer adding $200M biologics facility to Andover, MA, campus 
South Korea's Samsung Bioepis gets EU nod for Enbrel biosimilar


Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.